Events

Vermillion to Present at the

29th Annual Piper Jaffray Healthcare Conference

 

AUSTIN, Texas, November 20, 2017 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, being held at the Lotte New York Palace Hotel in New York City on November 28-29, 2017.

Presentation Details

Date:               Wednesday, November 29

Time:              12:30pm Eastern Time

Location:        The Lotte New York Palace Hotel, Track 5, Hubbard 1, 5th Floor

 

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

 

Investor Relations Contact:

Michael Wood

LifeSci Advisors LLC

Tel 1-646-597-6983

mwood@lifesciadvisors.com

Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum

AUSTIN, Texas, November 6, 2017 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City on November 9, 2017.

Date:               Thursday, November 9

Time:              3:30pm Eastern Time

Location:        Track 5

 

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:

Michael Wood

LifeSci Advisors LLC

Tel 1-646-597-6983

mwood@lifesciadvisors.com

Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th

 

Valerie Palmieri, President and Chief Executive Officer of Vermillion Inc., will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10 in Boston, Massachusetts.

 

Presentation Details

Date:                           Thursday, August 10

Time:                          1:00pm Eastern Time

Location:                    InterContinental Boston Hotel, Hong Kong Room

Canaccord Tenuity, Medical Technologies & Diagnostics Forum

November 17, 2016

Westin Grand Central Hotel

New York, New York

AAGL 45th Annual Global Congress

November 14-18, 2016

The Rosen Hotel

Orlando, Florida

Third Quarter 2016 Financial Results and Investor Conference Call

November 10, 2016 at 4:30 p.m. EST

Join by phone:

  • Domestic: 1-888-296-4197
  • International: 1-719-2462
  • Conference ID: 6709878

Join by webcast, here.

Replay dial-in numbers (available through): November 24, 2016

  • Domestic: 1-844-512-2921
  • International: 1-412-317-6671
  • Replay PIN: 6709878

PATHWAYS Webinar:

Understanding New Changes to the OVA1 Results Report

November 3, 3016

East Coast: 12:30-12:45 p.m. EST

West Coast: 12:30-12:45 p.m. PST

Presented by: Dr. Marra Francis, Chief Medical Officer of Vermillion and Dr. Herb Fritsche, Lab Director of ASPiRA Labs

Register for East Coast, here.

Register for West Coast, here.

For Investors

A Vermillion Investor Overview

We are dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women.